Literature DB >> 21288169

Laboratory assessment of new anticoagulants.

Meyer M Samama1, Céline Guinet.   

Abstract

With the introduction of new anticoagulant agents, there is a need for information on which coagulation tests are most suitable. These agents react differently to assays used to monitor older anticoagulant agents because they have alternative modes of action. Therefore, other tests, or modifications of existing tests which are more appropriate for newer agents, are needed. The prothrombin time test (with conversion to the international normalized ratio) is usually used to monitor warfarin. However, conversion to the international normalized ratio is not appropriate for measuring the effects of fondaparinux, dabigatran, rivaroxaban or apixaban. Instead, chromogenic assays, one-step prothrombinase-induced clotting time test and the HepTest with reduced incubation time, are among the different or modified tests that appear to give the most reproducible and accurate results. The tests show variations in response to anticoagulants - some of which have clinical relevance. Thus, it is important to be aware of the observed variations in order to prevent the misinterpretation of test results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21288169     DOI: 10.1515/CCLM.2011.134

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  41 in total

Review 1.  [New oral anticoagulants. Significance for dermatology and phlebology].

Authors:  M Hahn; V Hach-Wunderle
Journal:  Hautarzt       Date:  2012-08       Impact factor: 0.751

2.  Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants.

Authors:  Nur A Rahmat; Gregory Y H Lip
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-08

Review 3.  Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants.

Authors:  Ekta Y Pandya; Beata Bajorek
Journal:  Patient       Date:  2017-04       Impact factor: 3.883

Review 4.  Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

Authors:  Sascha Meyer Dos Santos; Sebastian Harder
Journal:  Drug Saf       Date:  2014-05       Impact factor: 5.606

Review 5.  [New anticoagulants. Characteristics, monitoring and management of bleeding].

Authors:  K Heidinger; B Kemkes-Matthes
Journal:  Med Klin Intensivmed Notfmed       Date:  2011-10-20       Impact factor: 0.840

Review 6.  Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal.

Authors:  Larry R Jackson; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

Review 7.  Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors:  Jochen Graff; Sebastian Harder
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

Review 8.  Reversal of novel oral anticoagulants in patients with major bleeding.

Authors:  Deborah M Siegal; Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 9.  Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.

Authors:  Sebastian Harder; Jochen Graff
Journal:  Eur J Clin Pharmacol       Date:  2013-04-26       Impact factor: 2.953

10.  Medical management of venous thromboembolism: what the interventional radiologist needs to know.

Authors:  Raj S Kasthuri; Nigel S Key
Journal:  Semin Intervent Radiol       Date:  2012-03       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.